Abstract
GABA receptors were characterized in vivo by studying ex vivo the binding of [3H]muscimol to cerebellum, cortex, hippocampus and corpus striatum of mice receiving i.v. injections of tracer doses of high-specific activity (.apprxeq. 30 Ci/mmol) [3H]muscimol. This ligand binds with high affinity (apparent Kd, 2-3 .times. 10-9 M) to a single population of binding sites (apparent Bmax [maximum binding], 250-180 fmol/10 mg protein). Pharmacologic studies using drugs that selectively bind to GABAA or GABAB receptors suggest that [3H]muscimol specifically labels a GABAA recognition site. Diazepam (1.5 .mu.mol/kg, i.p.) increases the Bmax but fails to change the affinity of [3H]muscimol binding to different brain areas. This diazepam-elicited increase in Bmax is blocked in mice receiving the diazepam antagonist Ro 15-1788 (ethyl-8-fluoro-5,6-dihydro-5-methyl-6-oxo-4H-imidazo[1,5a]-[1,4]benzodiazepine-3-carboxylate). Since the diazepam-induced increase of [3H]muscimol binding is paralleled by a significant potentiation of the inhibitory effect of muscimol on locomotor activity, the facilitatory action on GABAergic transmission elicited in vivo by diazepam may be mediated by an increase in the Bmax of the binding sites of GABAA receptors.